Alice Flaherty, MD, PhD.
Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.
Dr. Flaherty has no financial relationships with companies related to this material.
Sébastien Hardy, MD. Dr. Hardy has no financial relationships with companies related to this material.
Brian Holoyda, MD. Chief Psychiatrist, Contra Costa County Detention Health Services, Martinez, CA. Dr. Holoyda has no financial relationships with companies related to this material.
Jeremy Mills, DNP, PMHNP-BC. Dr. Mills has no financial relationships with companies related to this material.
Maureen C. Nash, MD.
Medical Director, Providence ElderPlace PACE Oregon. Co-editor, Neurocognitive Behavioral Disorders: An Interdisciplinary Approach to Patient-Centered Care (Springer; 2019). All comments are Dr. Nash’s personal views and not those of any organization.
Dr. Nash has no financial relationships with companies related to this material.
Paul S. Appelbaum, MD
Dollard Professor of Psychiatry, Medicine, & Law; Director, Center for Law, Ethics, and Psychiatry, Columbia University, New York, NY. Co-author of Assessing Competence to Consent to Treatment (Oxford University Press; 1998).
Dr. Appelbaum has no financial relationships with companies related to this material.
Michael J. Gitlin, MD.
Professor of Clinical Psychiatry and Director of the Mood Disorders Clinic at the David Geffen School of Medicine at UCLA; coauthor of The Essential Guide to Lithium Treatment (Springer, 2016).
Dr. Gitlin has no financial relationships with companies related to this material.
Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.
Dr. Abelleira has no financial relationships with companies related to this material.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
